StockNews.AI
BCRX
StockNews.AI
120 days

BioCryst to Report First Quarter 2025 Financial Results on May 5

1. BioCryst will report Q1 2025 results on May 5, 2025. 2. Management plans a conference call to discuss financials and updates. 3. BioCryst focuses on oral treatments for rare diseases like hereditary angioedema. 4. The company commercialized ORLADEYO®, its first plasma kallikrein inhibitor. 5. Webcast and replay of the call will be available online.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming earnings report can influence investor sentiment positively, especially if results are strong. Historical trends indicate market excitement often surrounds such announcements in biotech.

How important is it?

The company's earnings report is likely to sway investor confidence and affect stock performance in the short term.

Why Short Term?

The earnings report will likely lead to immediate reactions based on reported performance and projections.

Related Companies

BCRXVRTXALNY
April 21, 2025 07:00 ET  | Source: BioCryst Pharmaceuticals, Inc. RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn. BCRXW Contact:John Bluth+1 919 859 7910jbluth@biocryst.com

Related News